Supplementary Table 1. Therapeutic and Pathologic Characteristics of the US and Mammography Group

Characteristic	Mammography (n = 197)	US (n = 43)	Р
Surgery type			< 0.001
Breast-conserving surgery	73 (37.1)	32 (74.4)	
Total mastectomy	124 (62.9)	11 (25.6)	
invasiveness			0.955
Non-invasive	42 (21.3)	9 (20.9)	
Invasive	155 (78.7)	34 (79.1)	
Tumor size (cm)	1.332 ± 1.074	1.154 ± 0.839	0.306
stage			0.708
TO	42 (21.3)	9 (20.9)	
T1	113 (57.4)	28 (65.1)	
T2	42 (21.3)	6 (14.0)	
T3	0 (0)	0 (0)	
T4	0 (0)	0 (0)	
N stage			0.693
NO	147 (74.6)	36 (83.7)	
N1	32 (16.2)	4 (9.3)	
N2	12 (6.1)	2 (4.7)	
N3	6 (3.1)	1 (2.3)	
Histologic grade			
Not-high	137 (69.5)	28 (83.7)	0.060
High	60 (30.5)	4 (16.3)	
Chemotherapy			0.799
Absent	92 (46.7)	21 (48.8)	
Present	105 (53.3)	22 (51.2)	
Endocrine therapy			0.066
Absent	59 (29.9)	7 (16.3)	
Present	137 (69.6)	36 (83.7)	
N/A	1 (0.5)	0 (0)	
Radiation therapy			< 0.001
Absent	106 (53.8)	8 (18.6)	
Present	91 (46.2)	35 (81.4)	
Estrogen receptor			0.281
Negative	57 (28.9)	9 (20.9)	
Positive	135 (68.6)	33 (76.7)	
N/A	5 (2.5)	1 (2.3)	
Progesterone receptor	· ,	. ,	0.206
Negative	60 (30.5)	9 (20.9)	
Positive	132 (67.0)	33 (76.8)	
N/A	5 (2.5)	1 (2.3)	
HER2 receptor	,	, <i>,</i>	0.465
Negative	123 (62.5)	31 (72.1)	
Positive	41 (20.8)	6 (14.0)	
Unknown	28 (14.2)	5 (11.6)	
N/A	5 (2.5)	1 (2.3)	

Results are expressed as numbers (percents), with means \pm standard deviations (ranges). Differences were significant if the p value was less than 0.05. $HER2 = human\ epidermal\ growth\ factor\ receptor\ 2$, $N/A = not\ available$, US = ultrasound